Cerebrolysin's Position: Decades of clinical use across 40+ countries with established safety and efficacy data Meta-analyses and Cochrane systematic reviews the highest levels of clinical evidence Known limitations: complex mixture makes precise mechanism attribution difficult, not FDA-approved, requires IV/IM administration Represents validated but incrementally effective neurotrophic therapy Dihexa's Position: Exceptional mechanistic novelty HGF/c-Met potentiation at picomolar concentrations is a genuinely unique pharmacological finding if confirmed Entirely preclinical with no human data of any kind Foundational research compromised by expression of concern and retraction the core evidence base is actively questioned Theoretical safety concerns (c-Met oncogenesis) that have not been addressed experimentally Represents frontier neuroscience that has not survived the basic tests of scientific reproducibility For Researchers: Cerebrolysin offers a clinically validated tool for studying neurotrophic effects in humans, supported by the strongest available evidence
If symptoms persist, consult a healthcare professional
The freeze-drying process removes water, and without water, the chemical reactions that break down peptide bonds essentially stop
Pathogen Activation: Dormant infections like viruses or bacteria may become active and worsen damage
Our highly-skilled specialists make sure each patient with Barretts esophagus has a thorough diagnosis and individualized treatment plan
Substances labeled "research use only" or "not for human consumption" are prohibited under this classification, regardless of their marketed claims
